Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Does alcohol slow down your ED meds? new study investigates

NCT ID NCT07290400

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether having a moderate amount of alcohol changes how quickly and how well a liquid form of sildenafil (the active ingredient in Viagra) works for erectile dysfunction. Thirty-six men will take the medication under different conditions—with and without alcohol—to compare absorption and onset of effect. The goal is to provide clearer guidance on using this medication alongside alcohol.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hezkue sildenafil oral suspension
What this could lead to
If successful, this could show that moderate alcohol does not interfere with how quickly or well sildenafil works, helping guide real-world use.
What could go wrong
This is a small, early-phase study (36 people) focused on absorption, not on long-term effectiveness or safety. Results may not apply to heavy drinking or other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male adults 21 to 65 years of age, inclusive * Documented history of erectile dysfunction for at least 6 months, as determined by the investigator * In a stable sexual relationship and willing to attempt sexual activity as required by study procedures, if applicable * Medically stable based on medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations, in the opinion of the investigator * Able, in the investigator's judgment, to safely consume moderate amounts of alcohol as defined in the protocol * Willing to abstain from alcohol outside of protocol-specified intake during the study * Able to understand and provide written informed consent before any study-specific procedures are performed * Willing and able to comply with all study procedures, including dosing, washout periods, pharmacokinetic sampling, onset assessments, and safety monitoring Exclusion Criteria: * Known hypersensitivity or contraindication to sildenafil, other PDE5 inhibitors, alcohol, or any component of the Hezkue® formulation * Use of nitrates, nitric oxide donors, guanylate cyclase stimulators (such as riociguat), or other prohibited medications within a protocol-defined period * Clinically significant cardiovascular disease, including coronary artery disease, heart failure, clinically important arrhythmias, recent stroke, or uncontrolled hypertension or hypotension * Resting blood pressure or heart rate outside protocol-defined acceptable ranges at screening or baseline, in the opinion of the investigator * Significant hepatic, renal, neurologic, psychiatric, endocrine, hematologic, or respiratory disease that could increase risk or interfere with study assessments * History of syncope, significant orthostatic hypotension, or other conditions that may be worsened by sildenafil or alcohol * History of alcohol use disorder, binge drinking, or other substance use disorder, as determined by the investigator * Positive urine drug screen or positive alcohol test at screening or admission (outside protocol-specified alcohol administration) * Use of prescription or over-the-counter medications, herbal products, or dietary supplements within 14 days before first dosing unless approved by the investigator * Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV * Participation in another clinical study or receipt of an investigational product within 30 days or 5 half-lives, whichever is longer * Donation of 450 mL or more of blood, or significant blood loss, within 8 weeks before first dosing * Any condition or circumstance that, in the opinion of the investigator, would make the participant unsuitable or interfere with study conduct or interpretation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Erectile dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.